We found no difference in the surface expression of SIRL-1 between healthy and ex vivo SLE neutrophils (Figure 3D and E), supporting the idea of targeting SIRL-1 as a potential way of suppressing neutrophils and the release of NETs in SLE. Here, VSTM1 is linked to systemic lupus erythematosus.